CCDC110 Activators
Common CCDC110 Activators include, but are not limited to 5-Azacytidine CAS 320-67-2, Trichostatin A CAS 58880-19-6, Suberoylanilide Hydroxamic Acid CAS 149647-78-9, Sodium Butyrate CAS 156-54-7 and Resveratrol CAS 501-36-0.
CCDC110, or Coiled-Coil Domain Containing 110, is a protein-coding gene recognized for its role in protein binding. It's a member of the broader CCDC family, many of which are implicated in the pathogenesis of various diseases. In specific contexts, CCDC110 has been pinpointed as a potential prognostic marker in renal cancer, suggesting a favorable prognosis for those expressing it. Furthermore, its status as a novel human cancer/testis antigen means it can elicit both cellular and humoral immune responses. Intriguingly, its predicted cellular locations are the nucleus and cytoskeleton, reinforcing its importance in cellular dynamics.
The chemical class of CCDC110 Activators encompasses compounds designed to amplify the activity or expression of the CCDC110 protein. Such activators might enhance CCDC110 functionality by either direct interaction or modulation of associated signaling pathways. Their potential actions could lead to a boosted immune response against cancer cells, a change in cellular structural dynamics due to CCDC110's involvement in the cytoskeleton, or refined disease prognosis by adjusting CCDC110 expression levels. As CCDC110's involvement in tumor pathogenesis and other diseases becomes more evident, activators targeting this protein could offer a fresh perspective on novel strategies. Nonetheless, the comprehensive development and understanding of these activators warrant further rigorous research.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
As a DNA methyltransferase inhibitor, 5-Azacytidine may modulate epigenetic marks, potentially leading to increased expression of CCDC110. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
Trichostatin A is a histone deacetylase inhibitor that may enhance the acetylation of histones at the CCDC110 gene locus, possibly promoting its expression. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $130.00 $270.00 | 37 | |
SAHA, a histone deacetylase inhibitor, may also promote histone acetylation at the CCDC110 gene locus, potentially leading to increased expression. | ||||||
Sodium Butyrate | 156-54-7 | sc-202341 sc-202341B sc-202341A sc-202341C | 250 mg 5 g 25 g 500 g | $30.00 $46.00 $82.00 $218.00 | 19 | |
By inhibiting histone deacetylases, Sodium Butyrate might promote a more relaxed chromatin structure at the CCDC110 gene locus, potentially enhancing its expression. | ||||||
Resveratrol | 501-36-0 | sc-200808 sc-200808A sc-200808B | 100 mg 500 mg 5 g | $60.00 $185.00 $365.00 | 64 | |
Resveratrol is known to modulate various signaling pathways and might influence transcription factors or co-activators regulating CCDC110 expression. | ||||||
Retinoic Acid, all trans | 302-79-4 | sc-200898 sc-200898A sc-200898B sc-200898C | 500 mg 5 g 10 g 100 g | $65.00 $319.00 $575.00 $998.00 | 28 | |
As a well-known modulator of gene expression, Retinoic Acid may affect transcription factors or signaling pathways regulating CCDC110 expression. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $26.00 $92.00 $120.00 $310.00 $500.00 $908.00 $1821.00 | 46 | |
Genistein, a phytoestrogen, may also modulate estrogen receptor signaling and potentially affect CCDC110 expression. | ||||||
Dexamethasone | 50-02-2 | sc-29059 sc-29059B sc-29059A | 100 mg 1 g 5 g | $76.00 $82.00 $367.00 | 36 | |
Dexamethasone, a glucocorticoid, might modulate glucocorticoid receptor signaling pathways, potentially affecting CCDC110 expression. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is a MEK inhibitor that might modulate MAPK/ERK signaling pathways, potentially affecting CCDC110 expression. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Sorafenib, a multi-kinase inhibitor, might modulate various kinase signaling pathways associated with CCDC110 expression. | ||||||